secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001193125-25-118839
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica Q1 2025: YCANTH revenue $3.4M; dispensed 10,102 units (+16.7% QoQ)
--------------------------------------------------------------------------

- Net loss $9.7M ($0.10/share) vs. $20.3M ($0.44) in Q1 2024; non-GAAP net loss $7.8M.
- YCANTH revenue $3.4M from >10K applicator units dispensed, a company record and 16.7% sequential growth.
- Cash and equivalents $29.6M as of March 31, 2025.
- Appointed Noah Rosenberg as CMO (March) and Gavin Corcoran to Board (April).
- Completed end-of-Phase 2 meeting with FDA for VP-315 (basal cell carcinoma); global Phase 3 for common warts advancing with Torii.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525118839/0001193125-25-118839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525118839/d88474d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-118839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer